Harmony Biosciences Holdings (HRMY) Long-Term Deferred Tax (2022 - 2026)

Harmony Biosciences Holdings (HRMY) has 5 years of Long-Term Deferred Tax data on file, last reported at $153.6 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax fell 21.13% year-over-year to $153.6 million; the trailing twelve-month figure through Mar 2026 stood at $153.6 million (down 21.13% YoY), and the FY2025 full-year result was $149.7 million, down 21.38% from the prior year.
• Long-Term Deferred Tax grew to $153.6 million in Q1 2026, from $149.7 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $201.2 million in Q2 2025 to a low of $81.7 million in Q3 2022.
• A 5-year average of $143.6 million and a median of $149.7 million in 2025 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax soared 92.55% in 2024 and retreated 21.38% in 2025, its largest moves.
• Tracing HRMY's Long-Term Deferred Tax over 5 years: stood at $85.9 million in 2022, then jumped by 67.74% to $144.2 million in 2023, then jumped by 32.07% to $190.4 million in 2024, then dropped by 21.38% to $149.7 million in 2025, then rose by 2.58% to $153.6 million in 2026.
• Business Quant data shows HRMY's Long-Term Deferred Tax at $153.6 million in Q1 2026, $149.7 million in Q4 2025, and $157.1 million in Q3 2025.